Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
A former researcher at Amgen has been named as the new chief scientific officer of UK-based cellular immunotherapy company Cell Medica. 18 September 2017
Biotechnology
Alexandre Sudarskis, chief executive of privately-held Swiss biopharma firm Neovii Pharmaceuticals will step down from this post having reached retirement age. 15 September 2017
Pharmaceutical
In his second Expert View piece, Yungjoon Kwon, patent/trademark attorney and managing director at law firm Kwon & Kim, considers a South Korean court’s view on one of pharma's hottest topics – dosage regime drugs’ patentability. 14 September 2017
Pharmaceutical
Nicola Davies casts her eye over a fast-emerging field in pharma. 13 September 2017
Biotechnology
USA-based holding company PDL BioPharma has appointed Dominique Monnet to the position of president. 12 September 2017
Biotechnology
US biotech major Biogen has engaged Dr Sanjay Jariwala as senior vice president, worldwide medical. 12 September 2017
Generics
Danish CNS specialist Lundbeck saw its shares drop 11.58% to 364.20 Danish kroner this morning, when it was revealed that its chief executive Kåre Schultz is set to join Israeli generics behemoth Teva Pharmaceutical Industries as the latter’s president and CEO. 11 September 2017
Pharmaceutical
Mandatory immunization for children in India between nine months and 15 years of age against measles and rubella has not worked its charm, with India and Indonesia accounting for over 90% of unvaccinated children in Southeast Asia, according to the World Health Organization. Misconceptions and misinformation have turned out to be the main culprit, reports The Pharma Letter’s India correspondent. 11 September 2017
Biotechnology
While it’s not unheard of to find a biotech firm in the American Mountain States, it is unusual. In the case of Clovis Oncology, the explanation for its location in Colorado is clear, as co-founder and chief executive Pat Mahaffy explains: “I started the firm, and I live here.” 10 September 2017
Biotechnology
As competition in immuno-oncology hots up, in New York, a biotech startup called Rgenix has entered the fray with RGX-104, a small molecule currently entering Phase I. 8 September 2017
Biotechnology
US ophthalmology specialist Ocular Therapeutix (Nasdaq: OCUL) today announced the appointment of Michael Goldstein as chief medical officer. 8 September 2017
Pharmaceutical
Prices for drugs in Russia may increase by 15%-20% as soon as October of the current year, according to predictions of the Russian Ministry of Health reported by The Pharma Letter’s local correspondent. 5 September 2017
Biotechnology
Swiss pharma giant Roche will increase the level of localization in Russia through the establishment of full cycle of production of its Gaziva /Gazyvaro (obinutuzumab) antitumor drug, according to the company. 5 September 2017
Generics
Mark Engelman, head of intellectual property at UK-based law firm Hardwicke, offers his interpretation on a landmark ruling in an Expert View piece. 5 September 2017
Pharmaceutical
A view on the future of rare disease drug development and population health from Michelle Hoffmann, senior vice president of strategy consulting at Boston-based life science consultancy, Back Bay Life Science Advisors. 4 September 2017
Pharmaceutical
All eyes were on the share price of Swiss pharma giant Novartis on Monday after the announcement that Joe Jimenez was to step down from his role as chief executive. 4 September 2017
Pharmaceutical
On August 18, 2017, US President Donald Trump signed into law the Food and Drug Administration Reauthorization Act (FDARA) of 2017, extending the user fee program that was to expire on September 30, 2017.1 This legislation includes the Prescription Drug User Fee Amendments of 2017 (PDUFA VI) and the General Drug User Free Amendments (GDUFA). 4 September 2017
Generics
Bain Capital and Cinven announce their intention to nominate Claudio Albrecht as new chief executive and Mark Keatley as new chief financial officer of Stada Arzneimittel, the German generic drugmaker they are in the process of acquiring. 4 September 2017
Pharmaceutical
News on chimeric antigen receptor T-cell (CAR-T) therapies in the last week has added to the immediacy of a question that has been hanging over these individually-tailored cancer treatments as they have edged closer to market – how on earth are health systems going to afford them? 1 September 2017
Pharmaceutical
German family-owned pharma company Grünenthal Group today announces that Mark Fladrich has taken office as new chief commercial officer (CCO). 1 September 2017
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze